Therapy of renal cell carcinoma. 3. Interferon therapy

Human lymphoblastoid interferon (HLBI-alpha) or recombinant human leukocyte interferon (HLIF-alpha) was administered to ten patients suffering from renal cell carcinoma at a daily dose of 5 X 10(6) units. The efficacy of interferon was assessed in nine patients who had received HLBI-alpha or HLIF-al...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 33(1987), 4 vom: 01. Apr., Seite 508-14
1. Verfasser: Kobayashi, M (VerfasserIn)
Weitere Verfasser: Imai, K, Kiren, H, Nakai, K, Saruki, K, Umeyama, T, Ito, Y, Yamanaka, H, Makino, T, Machida, M
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 1987
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Case Reports English Abstract Journal Article Interferon Type I Recombinant Proteins
LEADER 01000caa a22002652 4500
001 NLM03599679X
003 DE-627
005 20250126213328.0
007 tu
008 231221s1987 xx ||||| 00| ||jpn c
028 5 2 |a pubmed25n0120.xml 
035 |a (DE-627)NLM03599679X 
035 |a (NLM)3618421 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a jpn 
100 1 |a Kobayashi, M  |e verfasserin  |4 aut 
245 1 0 |a Therapy of renal cell carcinoma. 3. Interferon therapy 
264 1 |c 1987 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 03.09.1987 
500 |a Date Revised 15.11.2007 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Human lymphoblastoid interferon (HLBI-alpha) or recombinant human leukocyte interferon (HLIF-alpha) was administered to ten patients suffering from renal cell carcinoma at a daily dose of 5 X 10(6) units. The efficacy of interferon was assessed in nine patients who had received HLBI-alpha or HLIF-alpha for more than eight weeks. One patient (11%) demonstrated complete response (CR), three patients (33%) showed no change and five patients (56%) continued to have progressive disease. CR was obtained after 30 weeks under HLBI-alpha and FT-207 combination therapy. The main side effects were fever, anorexia, general fatigue and hematologic toxicities. Cessation of interferon therapy due to side effects was necessary in three patients. In conclusion interferon is one of the most valuable agents in the treatment of renal cell carcinoma 
650 4 |a Case Reports 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a Interferon Type I  |2 NLM 
650 7 |a Recombinant Proteins  |2 NLM 
700 1 |a Imai, K  |e verfasserin  |4 aut 
700 1 |a Kiren, H  |e verfasserin  |4 aut 
700 1 |a Nakai, K  |e verfasserin  |4 aut 
700 1 |a Saruki, K  |e verfasserin  |4 aut 
700 1 |a Umeyama, T  |e verfasserin  |4 aut 
700 1 |a Ito, Y  |e verfasserin  |4 aut 
700 1 |a Yamanaka, H  |e verfasserin  |4 aut 
700 1 |a Makino, T  |e verfasserin  |4 aut 
700 1 |a Machida, M  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Hinyokika kiyo. Acta urologica Japonica  |d 1962  |g 33(1987), 4 vom: 01. Apr., Seite 508-14  |w (DE-627)NLM012631779  |x 0018-1994  |7 nnns 
773 1 8 |g volume:33  |g year:1987  |g number:4  |g day:01  |g month:04  |g pages:508-14 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_40 
912 |a GBV_ILN_60 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_350 
912 |a GBV_ILN_2001 
912 |a GBV_ILN_2003 
912 |a GBV_ILN_2005 
912 |a GBV_ILN_2006 
912 |a GBV_ILN_2008 
912 |a GBV_ILN_2010 
912 |a GBV_ILN_2012 
912 |a GBV_ILN_2018 
951 |a AR 
952 |d 33  |j 1987  |e 4  |b 01  |c 04  |h 508-14